Bristol Myers Squibb shares preliminary KarXT trial data

Bristol Myers Squibb (BMY) presented preliminary Phase 3 data from its ADEPT trials for KarXT in treating psychosis related to Alzheimer’s disease. The studies showed mean reductions in hallucinations and delusions, with adverse events reported. KarXT is FDA-approved for schizophrenia. No treatments are currently approved for Alzheimer’s-related psychosis.

Original reporting
Published Nov 18, 2026, 2:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 2:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$BMY
Bullish
medium confidence
Mentioned
$BMY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BMYBullishMed
01

Why it matters

The disclosed symptom-scale reductions and discontinuation rates provide early efficacy and tolerability signals, but the lack of unblinded double-blind treatment-period results keeps regulatory and commercial confidence incomplete.

02

Market read

Traders may adjust biotech risk exposure based on early read-through of efficacy and safety, while waiting for unblinded double-blind data to confirm signal strength.

03

What to watch

Adverse-event rates are high in both studies (56.6% and 65.1%), and the article notes ongoing trials and exclusion of participants still ongoing at cutoff, which can affect interpretability.

Relevance 7/10Novelty 6/10Timing: at the Clinical Trials on Alzheimer’s Disease conference, with data presented Tuesday

Background

KarXT (xanomeline plus trospium chloride) is FDA-approved as Cobenfy for schizophrenia; ADEPT Phase 3 program is evaluating it for psychosis associated with Alzheimer’s disease.

Company-level read

Ticker impact

$BMYBullishMedium confidence
Context

Bristol Myers Squibb reported preliminary Phase 3 ADEPT open-label data for KarXT in Alzheimer’s-associated psychosis, including hallucination/delusion score reductions and adverse-event rates.

Expected impact

Likely modest upside bias as investors price in potential clinical benefit, tempered by the open-label nature and ongoing blinded double-blind data.

Evidence & confidence

The article provides specific symptom-scale reductions and discontinuation/adverse-event percentages, which are decision-relevant for biotech trial read-through, but it explicitly excludes blinded double-blind outcomes and is labeled preliminary/descriptive.

Market effects

Strengthens the Alzheimer’s psychosis treatment pipeline narrative and may increase competitive attention on muscarinic-agonist approaches and trial endpoints.

Limited direct regional spillover; primarily impacts US-listed biotech sentiment around CNS and Alzheimer’s pipeline progress.

Conference-stage clinical updates can influence global biotech risk appetite for CNS assets, though final regulatory relevance depends on blinded efficacy data.

Counterpoint

Open-label, descriptive analyses can overstate benefit versus controlled data; investors may fade the move until double-blind results unblind.

Key entities

  • Bristol Myers Squibb

    Sponsor of the ADEPT Phase 3 program evaluating KarXT for Alzheimer’s-associated psychosis.

  • KarXT

    Xanomeline plus trospium chloride; being studied for psychosis associated with Alzheimer’s disease.

  • ADEPT-1 and ADEPT-3

    Open-label studies within the ADEPT clinical trial program; double-blind periods remain blinded.

Related articles

$BMYMed

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

Bristol Myers Squibb (BMY) shared preliminary Phase 3 data for KarXT in treating psychosis linked to Alzheimer's. ADEPT-1 showed improvements in hallucination and delusion scores over 12 weeks. ADEPT-3 reported long-term safety and tolerability data over 52 weeks. Both studies observed symptom score improvements and a favorable safety profile.

$MRKMedAI 8/10

AHA 2026: Pharmacists at the Center of Cardiometabolic Care

At AHA 2026, data on new cardiometabolic therapies highlighted pharmacists' growing role. Survodutide (Zealand Pharma, Boehringer Ingelheim) showed cardiovascular safety. Enlicitide (Merck) sustained LDL-C reductions. Stanford's model embedded pharmacists in heart failure care. Orforglipron (Eli Lilly) lowered systolic blood pressure. Pharmacists were noted for their critical roles in titration, adherence, and monitoring.

$BMYHigh

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb (BMY) is expanding its cardiovascular franchise with label expansions for Camzyos, including pediatric approvals, driving sales growth. Camzyos sales surged 61% YoY to $1.1B in 9 months. Eliquis, a key revenue driver, saw $13.3B in sales, up 21% YoY. BMY faces competition from Cytokinetics (CYTK) and Edgewise Therapeutics (EWTX) in the oHCM market. BMY shares gained 15.5% YTD, trading at 9.52X forward earnings.

$GSKMedAI 8/10

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.